期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

泛素特异性肽酶22在胃癌中的表达及其临床意义 被引量：2

Expression of USP22 in gastric cancer and the clinical significance
下载PDF
导出
摘要 目的探讨泛素特异性肽酶22（USP22）在胃癌组织中的表达及意义。方法采用免疫组织化学SABC法检测100例胃癌、46例癌旁正常组织中USP22的表达情况。结果USP22在胃癌组织中阳性率为80．0％，明显高于正常组织（P〈0．05）。胃癌病理分期越高，USP22蛋白阳性表达率越高（P〈0．05）。胃癌分化程度越低，USP22蛋白阳性表达率越高（P〈0．05）。结论USP22是胃癌潜在的分子标记物。 Objective To investigate the expression of USP22 in gastric cancer and the clinical significance. Methods The expression of USP22 protein was detected in 100 cases of gastric cancer and 46 normal tissues by immunohistochemistry. Results The expression of USP22 was significantly higher in gastric cancer than normal tissues（P 〈0. 05）. The positive expression rate of USP22 in gastric cancer was positively correlated with stage （P 〈0. 05）, but negatively with differentiation （P 〈0. 05）. Conclusion USP22 was a potential biomarker of gastric cancer.
作者 邓美洲 陶凯雄 王国斌 刘兴华
机构地区 华中科技大学同济医学院附属协和医院腹腔镜外科
出处 《腹部外科》 2011年第5期302-303,共2页 Journal of Abdominal Surgery
关键词 胃肿瘤 泛素类 肽水解酶类 免疫组织化学 Stomach neoplasms Ubiquitins Peptide hydrolases Immunohistochemistry
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1骆杨,曾甫清,顾朝辉,汪良,王智宇,蒋国松,肖行远.膀胱移行细胞癌中候选肿瘤干细胞标记物USP22mRNA水平定量分析及其与肿瘤分级的关系[J].临床泌尿外科杂志,2009,24(2):140-144. 被引量：7
  • 2Liu YL,Yang YM, Xu H, et al. Increased expression of ubiquit- in-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Crastroenterol Hepa- tol,2010,25 : 1800-1805.
  • 3Katz E J, Isasa M, Crosas B. A new map to understand deubiquiti- nation. Biochem Soc Trans, 2010,38 (Pt l ) : 21-28.
  • 4Shabek N, Ciechanover A. Degradation of ubiquitin: the fate of the cellular reaper. Cell Cycle, 2010,9: 523-530.
  • 5Lee HJ, Kim MS, Shin J M, et al. The expression patterns of deu- biquitinating enzymes, USP22 and Usp22. Gene Expr Patterns, 2006,6: 277-284.
  • 6Zhang XY,Varthi M, Sykes SM, et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex re- quired for activated transcription and cell-cycle progression. Mol Cell,2008,29:102-111.
  • 7Zhao Y, Lang G, Ito S, et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear re- ceptors, and counteracts heterochromatin silencing. Mol Cell, 2008,29: 92-101.
  • 8Glinsky GV. Death-from-cancer signatures and stem cell contri- bution to metastatic cancer. Cell Cycle, 2005,4:1171-1175.
  • 9Lv L,Xiao XY, Gu ZH, et ak Silencing USP22 by asymmetric struc- ture of interfering RNA inhibits proliferation and induces cell cycle ar- rest in bladder cancer cell. Mol Cell Bloc.hem,2011,346.. 11-21.

二级参考文献8

  • 1Lee H J, Kim M S, Shin J M, et al. The expression patterns of deubiquitinating enzymes, USP22 and USP22[J]. Gene Expr, 2006, 6:277--284.
  • 2Glinsky G V. Genomic models of metastatic cancer: functional analysis of death from cancer signature genes reveals aneuploid, anoikis-resistant, metastasis enabling phenotype with altered cell cycle control and activa- ted Polycomb Group (PEG) protein chromatin silencing pathway[J]. Cell Cycle, 2006, 5:1208 -1216.
  • 3Ingvarsdottir K, Krogan N J, Emre N C, et al. H2B ubiquitin protease Ubp8 and Sgf11 constitute a discrete functional module within the Saccharomyces cerevisiae SAGA complex[J]. Mol Cell Biol, 2005, 25: 1162-- 1172.
  • 4George A A, Franklin J, Kerkof K, etal. Detection of leuke2 mic cells in the CD34 (+) CD38 (- ) bone marrow progenitor population in children with acute lymphoblastic leukemia[J]. Blood, 2001, 97: 3925--3930.
  • 5Miyamoto T, Weissman I L, Akashi K. AML1/ ETO2ex2 pressing nonleukemic stem cells in acute my elogenous leuke2 mia with 8: 21 chromosomal t ranslocation[J]. Proc Natl A cad Sci, 2000, 97: 7521- 7526.
  • 6Hanshan D, Weiberg R A. The hall marks of cancer [J]. Cell,2000,100(1):57-70.
  • 7Lee K K, Workman J L. Histone acetyhransferase complexes: one size doesn't fit all[J].Nature reviews, 2007, 8:284--295.
  • 8Zhang X Y, Varthi M, Sykes S M, etal. The Putative Cancer Stem Cell Marker USP22 Is a Subunit of the Human SAGA Complex Required for Activated Transcription and Cell-Cycle Progression [J]. Mol Cell, 2008, 29(1):102 -111.

共引文献6

同被引文献28

  • 1刘海,胡俊波,王志强,卫子然.MTA1基因表达与人胃癌的浸润和转移[J].世界华人消化杂志,2006,14(34):3317-3320. 被引量：6
  • 2蔡敏,孔香云,王妍,刘志艳,周志强,马榕,张庆慧.乳腺分叶状肿瘤EGFR、Ki67的表达和意义[J].中国现代普通外科进展,2007,10(3):247-250. 被引量：3
  • 3Lee ILl, Kim MS,Shin JM,et al. The expression patterns of deubiquitinating enzymes, USP22 and Usp22 [J]. Gene Expr Patterns, 2006,6(3) : 277-284.
  • 4Zhuang Y, Liao Z, Yu H, et al. ShRNA-mediated silencing of the ubiquitin-specifie protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyn- geal carcinoma [J]. Cancer Biology & Therapy,2014,16(1) : 88-96.
  • 5Glinsky GV, Berezovska O, Glinskii AB. Microarray analy- sis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer [J]. J Clin Invest,2005,115(6) : 1505-1521.
  • 6Liu YL,Jiang SX,Yang YM,et al. USP22 acts as an onco- gene by the activation of BMI-I-mediated INK4a/ARF pathway and Akt pathway [J]. Cell Biochem Biophys,2012, 62(I) :229-235.
  • 7Liu Y,Yang Y,Xu H,et al. Implication of USP22 in the regulation of BMI-I, c-Myc, pl6INK4a, pl4ARF, and cyclin D2 expression in primary colorectal carcinomas [J]. Diagn Mol Pathol,2010,19(4) : 194-200.
  • 8Zhang XY,Varthi M,Sykes SM,et al. The putative can- cer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression [J]. Mol Cell, 2008,29(1) : 102-111.
  • 9Schrecengost RS,Dean JL,Goodwin JF,et al. USP22 reg- ulates oncogenic signaling pathways to drive lethal can- cer progression [J]. Cancer Res,2014,74(1) :272-286.
  • 10Liu YL,Yang YM, Xu H,et al. Aberrant expression of USP22 is associated with liver metastasis and poor prog- nosis of colorectal cancer [J]. J Surg Oncol,2011,103 (3): 283-289.

引证文献2

二级引证文献11

腹部外科
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部